Patent US5484601A successfully refreshed from Google Patents.
US5484601A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Flowable demineralized bone powder composition and its use in bone repair
Assignee: Warsaw Orthopedic Inc
•
Filing: 1991-10-18
•
Granted: 1996-01-16
•
Expires: 2011-10-18
Abstract
Abstract A flowable demineralized bone powder composition is provided for use in surgical bone repair.
Inventors
- 👤 Robert K. O'Leary
- 👤 Patrick A. McBrayer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:16
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3604; A61L27/3608; A61K; A61K35/00; A61K35/12; A61K35/32; A61L24/00; A61L24/0005; A61L27/14; A61L27/22; A61L27/227; A61L27/3641; A61L27/3645; A61L27/365; A61F; A61F2/00; A61F2/02; A61F2/28; A61F2002/2835; A61L2400/00; A61L2400/06; A61L2430/00; A61L2430/02
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
96 words
A flowable composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth-inducing amount of demineralized osteogenic bone powder in a biocompatible liquid polyhydroxy compound and/or ester thereof as a carrier for the bone powder. wherein the liquid polyhydroxy compound and/or ester thereof is selected from the group consisting of glycerol monoesters and diesters of glycerol derived from low molecular weight carboxylic acids, ethylene glycol, diethylene glycol, triethylene glycol, 1,2-propanediol. trimethylolethane, trimethyolpropane, pentaerythritol, sorbitol, esters of any of the foregoing polyhydroxy compounds and mixtures thereof.
Claim 2
Dependent Claim
96 words
A flowable composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth-inducing amount of demineralized osteogenic bone powder in a biocompatible liquid polyhydroxy compound and/or ester thereof as a carrier for the bone powder. wherein the liquid polyhydroxy compound and/or ester thereof is selected from the group consisting of glycerol monoesters and diesters of glycerol derived from low molecular weight carboxylic acids, ethylene glycol, diethylene glycol, triethylene glycol, 1,2-propanediol. trimethylolethane, trimethyolpropane, pentaerythritol, sorbitol, esters of any of the foregoing polyhydroxy compounds and mixtures thereof.
Claim 3
Dependent Claim
24 words
The composition of claim 1 containing at least one additional ingredient selected from bone morphogenetic proteins, transforming growth factor and insulin-like growth factor IGD-1.
Claim 4
Dependent Claim
78 words
A flowable composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth-inducing amount of pulverized demineralized osteogenic bone powder in a biocompatible carrier for the bone powder, wherein said carrier is selected from the group consisting of glycerol, monoacetin, diacetin, and mixtures thereof, and wherein the composition contains at least one additional ingredient selected from bone morphogenetic proteins, transforming growth factor and insulin-like growth factor IGD-1.
Claim 5
Dependent Claim
78 words
A flowable composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth-inducing amount of pulverized demineralized osteogenic bone powder in a biocompatible carrier for the bone powder, wherein said carrier is selected from the group consisting of glycerol, monoacetin, diacetin, and mixtures thereof, and wherein the composition contains at least one additional ingredient selected from bone morphogenetic proteins, transforming growth factor and insulin-like growth factor IGD-1.
Claim 6
Dependent Claim
23 words
The composition of claim 1 wherein the average particle size of the demineralized bone powder is from about 0.1 to about 1.2 cm.
Claim 7
Dependent Claim
23 words
The composition of claim 1 wherein the average particle size of the demineralized bone powder is from about 0.2 to about 1 cm.
Claim 8
Dependent Claim
22 words
The composition of claim 1 wherein the demineralized bone powder is derived from cortical, cancellous and/or corticocancellous allogeneic or xenogeneic bone tissue.
Claim 9
Dependent Claim
17 words
The composition of claim 1 containing from about 5 to about 80 weight percent demineralized bone powder.
Claim 10
Dependent Claim
17 words
The composition of claim 1 containing from about 20 to about 60 weight percent demineralized bone powder.
Claim 11
Dependent Claim
72 words
The composition of claim 1 containing at least one additional ingredient selected from the group consisting of antiviral agent, antimicrobial agent, antibiotic agent, amino acid, peptide, vitamin, protein synthesis co-factor, hormone, endocrine tissue, synthesizer, enzyme, polymer-cell scaffolding agent with parenchymal cells, angiogenic drug, polymeric drug carrier, collagen lattice, antigenic agent, cytoskeletal agent, mesenchymal agent, bone digester, antitumor agent, cellular attractant, cellular attachment agent, immunosuppressant, nucleic acid, surface active agent and penetration enhancer.
Claim 12
Dependent Claim
28 words
The composition of claim 1 wherein said polyhydroxy compound comprises sorbitol dissolved in a solvent selected from the group consisting of glycerol, monacetin and diacetin and mixtures thereof.
Claim 13
Dependent Claim
41 words
The composition of claim 1 additionally comprising a thickener selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropyl methylcellulose, carboxy methylcellulose, pectin, food-grade texturizing agent, gelatin, dextran, collagen, starch, hydrolyzed polyacrylonitrile, hydrolyzed polyacrylamide and polyacrylic acid salt and mixtures thereof.
Claim 14
Dependent Claim
18 words
The composition of claim 1 wherein said demineralized osteogenic bone powder has been subjected to acid demineralization treatment.
Claim 15
Dependent Claim
18 words
The composition of claim 12 wherein said demineralized osteogenic bone powder has additionally been subjected to defatting/disinfecting treatment.
References Cited (Backward Citations)
US4191747A
Cited
SU880425A1
Cited
EP0082621A1
Cited
US4430760A
Cited
US4440750A
Cited
US4563489A
Cited
US5053049A
Cited
US5073373A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-01-15 | 1999-07-17 | 2000-01-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-01-15 | 2003-07-17 | 2004-01-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-01-15 | 2007-07-17 | 2008-01-16 | $7700.00 | Window Closed / Lapsed |